Retatrutide Peptide

Retatrutide may act on three receptors at once — GLP-1R, GIPR, and GCGR. Preclinical and clinical research suggests this triple action drives its profile. It is not approved by the FDA. No human safety data exists for research-grade material. Findings remain early, and long-term data are still evolving.

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly and classified as a triple hormone receptor agonist. It is the first compound in its class to reach Phase 3 research. Researchers study it because it engages three G protein-coupled receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). In human receptor binding assays it is most potent at GIPR (EC50 0.0643 nM), followed by GLP-1R (0.775 nM) and GCGR (5.79 nM). Its backbone is derived from GIP, stabilised by non-coded residues (Aib at positions 2 and 20; α-Me-Leu at position 13), with a C20 fatty diacid linker at Lys17 that binds albumin and extends systemic exposure. It is investigated as a reference tool in incretin pharmacology, obesity pathway research, energy-expenditure signalling, and metabolic dysfunction-associated steatotic liver disease (MASLD) models.

Disclaimer: Retatrutide is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

Chemical Properties of Retatrutide

How Does Retatrutide Work?

Retatrutide Peptide is thought to engage three receptor systems at the same time in experimental models. Each pathway is distinct but complementary. The mechanism below is drawn from receptor assays and preclinical data.

Picture the peptide docking at three separate cell-surface receptors. The GIP-backbone sequence and the albumin-binding fatty acid tail together are considered to enable this simultaneous engagement while extending tissue exposure time.

GLP-1R Pathway

Retatrutide binds GLP-1R with an EC50 of 0.775 nM in human receptor assays. On binding, the receptor couples to Gαs, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA) in pancreatic beta cells. In isolated-cell and rodent models this is associated with glucose-dependent insulin signalling, delayed gastric emptying, and hypothalamic appetite-circuit modulation. These observations are well characterised across the GLP-1R agonist class in peer-reviewed literature.

GIPR Pathway

Retatrutide is most potent at GIPR (EC50 0.0643 nM), roughly 8.9-fold above endogenous GIP at this receptor. In experimental models GIPR activation is associated with glucose-dependent insulin signalling and effects on adipose-tissue lipid handling. The interaction between GIPR and GLP-1R engagement has been characterised as a driver of the effects seen with dual and triple agonists versus GLP-1R alone.

GCGR Pathway

Retatrutide's engagement of GCGR (EC50 5.79 nM) is what separates it mechanistically from dual GLP-1R/GIPR agonists such as tirzepatide. In rodent models, GCGR activation is associated with elevated whole-body energy expenditure through thermogenic and lipolytic signalling. In preclinical comparisons, this component has been proposed as the basis for greater adipose reduction than tirzepatide — driven by increased energy expenditure rather than reduced intake alone, as reported in phase 2a research.

Albumin Binding and Extended Exposure

The C20 fatty diacid at Lys17 binds circulating albumin non-covalently. This slows renal filtration and extended the effective half-life to approximately 6 days in clinical pharmacokinetic studies, supporting once-weekly subcutaneous dosing in trial protocols. These figures apply to the trial formulation, not to research-grade material.

What Do Research Studies Show About Retatrutide?

Study data are early-stage and mixed across models. All findings below are from preclinical, in vitro, and clinical trial contexts. They do not constitute evidence of safety or efficacy for any non-approved use.

• Triple receptor engagement. Simultaneous GLP-1R, GIPR, and GCGR agonism characterised in receptor and structural studies, with EC50 values of 0.775, 0.0643, and 5.79 nM respectively.

• Phase 2 obesity data. In the phase 2 obesity trial, trial participants on 12 mg weekly showed mean weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks — the largest recorded for an incretin-class agent in a randomised trial at publication.

• Liver fat data. In a phase 2a MASLD study, mean relative liver-fat reductions of 81.4% (8 mg) and 82.4% (12 mg) at 24 weeks were observed in participants with baseline liver fat ≥10%.

• Glycaemic signalling. Phase 2 diabetes cohorts showed dose-dependent HbA1c changes alongside weight change, with a reported adverse-event profile comparable to approved GLP-1R agonists.

• Energy-expenditure mechanism. In rodent models, greater adipose reduction versus tirzepatide was attributed to GCGR-mediated energy expenditure rather than intake reduction alone.

Phase 3 programmes (TRIUMPH in obesity, TRANSCEND in type 2 diabetes, REDEFINE in MASLD) have begun reporting topline data, but peer-reviewed publications remain pending and findings may change.

What Are the Research Applications of Retatrutide?

Retatrutide is used as an experimental reference compound in metabolic and incretin pharmacology. The applications below are laboratory and clinical-research contexts only.

• Triple-agonism pharmacology. A primary tool for characterising simultaneous GLP-1R/GIPR/GCGR engagement in cAMP reporter assays, binding assays, and cryo-EM structural studies, within the broader field of incretin receptor pharmacology.

• Energy-expenditure pathway research. Investigated in rodent and cell models for the respective GLP-1R, GIPR, and GCGR contributions to observed body-weight change, with focus on the GCGR thermogenic component.

• MASLD models. Studied for hepatic fat content and steatohepatitis markers in fatty-liver models, examining GCGR-mediated hepatic fat oxidation alongside incretin-mediated insulin signalling.

• Glycaemic-signalling research. Used to probe glucose-dependent insulin secretion and insulin-sensitivity pathways in cell-based systems.

• Comparative incretin pharmacology. Employed as the triple-agonist reference against GLP-1R monotherapy (semaglutide) and dual GLP-1R/GIPR agonism (tirzepatide) to study receptor cross-talk and downstream signalling.

What Adverse Events Were Reported in Retatrutide Trials?

Gastrointestinal events were the most common finding in phase 2 populations. All observations below come from trial data and preclinical models, not from research-grade material.

• Gastrointestinal events (nausea, vomiting, diarrhoea, constipation) — most frequent, dose-dependent, predominantly mild-to-moderate; consistent with GLP-1R agonist class effects.

• Hypersensitivity and injection-site reactions — reported at low frequency with subcutaneous administration.

• Transient heart-rate increases — observed in phase 2 data; mechanism not fully characterised for the triple-agonist combination.

• Theoretical cardiovascular considerations from GCGR agonism — proposed on mechanistic grounds; no adverse cardiovascular signal was seen in phase 2 populations, but long-term data are not available.

• Pancreatitis — cannot be excluded; participants with significant pancreatitis history were excluded from phase 2 trials.

• Renal pharmacokinetic variability — participants with severe renal impairment were excluded; data in this population are limited.

No long-term human safety data have been established. These observations should not be extrapolated beyond the trial contexts in which they were recorded.

What Are the Risks and Limitations of Retatrutide Research?

This section is mandatory reading before working with Retatrutide in any laboratory setting.

Handling Precautions: Retatrutide should be handled by trained laboratory personnel only, in a controlled research environment. Use appropriate PPE at all times — nitrile gloves, lab coat, and eye protection at minimum. Work with lyophilized powder in a laminar-flow cabinet and avoid aerosol generation. Avoid direct skin contact or inhalation of any reconstituted solution.

Exposure Risks: Retatrutide is a triple hormone receptor agonist research peptide that is thought to engage GLP-1R, GIPR, and GCGR in preclinical models. Accidental exposure may engage these receptors in tissues expressing them; gastrointestinal effects are the primary expected acute response. No human safety data exists for this compound. Risk tier: MODERATE.

Storage: Store lyophilised Retatrutide at −20°C in a dry, dark environment. Protect from light, heat, moisture, and oxidising agents. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles, which may degrade the peptide backbone and fatty acid conjugate.

Toxicity and Data Limitations: No chronic toxicity data exist for Retatrutide. All findings are from short-duration preclinical and phase 2 models only, and evidence remains mixed across models.

What to Look for in a Supplier when buying research-grade Retatrutide?

Check that every batch is independently third-party tested for purity and identity, and that a Certificate of Analysis is available for each lot. You can try trusted sources like RCD Bio, where all compounds are sold strictly for preclinical and in vitro research use.

Note: All RCD Bio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Disclosure: This content is for informational purposes only and does not constitute an endorsement of any product for human use.

Frequently Asked Questions

What is Retatrutide, and what is it studied for?
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that engages three receptors — GLP-1R, GIPR, and GCGR. It is investigated in preclinical and clinical research for obesity-pathway pharmacology, metabolic signalling, hepatic fat models, and glycaemic-signalling research. It is not FDA approved and is for research use only.

How does Retatrutide differ from tirzepatide?
Tirzepatide is a dual GLP-1R/GIPR agonist. Retatrutide adds glucagon receptor (GCGR) agonism as a third mechanism. In preclinical models, GCGR activation is associated with increased energy expenditure — an effect not produced by GLP-1R or GIPR engagement alone. This difference is the proposed basis for its distinct profile in head-to-head preclinical comparisons.

Is Retatrutide approved by the FDA?
No. Retatrutide is not approved by the FDA for any indication. It is an investigational compound in Phase 3 research under the TRIUMPH, TRANSCEND, and REDEFINE programmes. It is supplied strictly for laboratory research and is not intended for human or veterinary use.

What is the half-life of Retatrutide?
In phase 2 clinical pharmacokinetic studies, the trial formulation showed an approximate half-life of 6 days after subcutaneous administration. This is attributed to the C20 fatty diacid at Lys17, which promotes albumin binding and slows renal clearance. These figures apply to the trial formulation, not research-grade material.

How should research-grade Retatrutide be stored?
Store lyophilised Retatrutide at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles, which may degrade the peptide backbone and disrupt the fatty acid conjugate. Protect from oxidative conditions.

What is Retatrutide's WADA status?
Retatrutide is prohibited under the 2026 WADA Prohibited List under S0 (non-approved substances) and S2 (peptide hormones and related substances). Researchers in sport-adjacent studies must verify the current status at GlobalDRO.com before use.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/

2. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38858523/

ATTENTION: This product is for LABORATORY AND RESEARCH PURPOSES ONLY. It is not for human or veterinary use. Retatrutide is not a dietary supplement and is not intended for human consumption or self-administration.